

MPN Research Foundation



180 N. Michigan Avenue, Suite
1870
Chicago IL 60601
(312) 683-7249
www.mpnresearchfoundation.org



Mission

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments – and eventually a cure – for myeloproliferative neoplasms (MPNs). In addition, the foundation promotes collaboration in the scientific community to accelerate research and serves as an advocacy group for patients and their families.

Strategy/Approach

The MPN Research Foundation's primary mission is to stimulate original MPN research in pursuit of new treatments and eventually a cure for polycythemia vera, primary myelofibrosis (MF), and essential thrombocythemia. The MPN Research Foundation promotes collaboration in the scientific community to accelerate MPN research, and serves as a powerful patient advocacy group for MPN patients and their families. The foundation has funded both basic and translational projects.

Its funding strategy, based on the premise that patients can change the course of their disease, is to:

- Fund scientific research of the highest potential for impact on MPNs
- Catalyze areas of science not being stimulated by other funding sources
- Focus on research with the highest potential to have transformative effects on patient care and treatment
- Leverage limited funds to get the largest return on investment

Research Portfolio

To date, the MPN Research Foundation has awarded more than \$9 million. Its portfolio of awards includes:

- **MPN Challenge Grant** – New in 2014, the Foundation is again partnering with LLS. We are seeking to award up to 10 grants in 5 focus areas:
 - *Fibrosis and the Bone Marrow Niche*
 - *CALR Mutation*
 - *Reducing MPN Allele Burden*
 - *Selective JAK2 Inhibition*
 - *Immunotherapy*
- **New Investigator Awards** – aimed at emerging investigators who are considering a career related to MPNs
- **Established Investigator Awards** – for researchers with a history of achievement in MPN research
- **MF Challenge Grant**—a joint grant program between the MPN Research foundation and the Leukemia & Lymphoma Society with the goal of discovering factors that induce fibrosis and identify opportunities to reverse this.

Partnership Practices

MPN Research Foundation accepts corporate sponsorships from biotech and pharmaceutical companies. The foundation accepts unrestricted monetary and in-kind donations from companies in the biotech, pharmaceutical, and related industries. It provides no goods, services, or benefits in return for these donations and makes no commitment to promote or endorse specific companies or products in any way. Past and current sponsors include Incyte, YM Biosciences Inc., Sanofi Aventis, Geron, and Celgene.

MPN Research Foundation does not partner with biotech and pharmaceutical companies.

Financials

MPN Research Foundation is a 501(c)(3) charitable organization. The most recent financial information available is from 2013.¹

Year ending 11/30/2013:

- Revenue: \$1,709,209
- Assets: \$1,010,479
- Expenses: \$1,704,766
- Grants: \$400,000

Key Accomplishments

- Has funded more than \$9 million in MPN research.
- Initiating \$1million investment in MPN research in 2014
- Funded first large-scale tissue bank and associated data bank at Mayo Clinic.
- Funded pivotal JAK2 pre-clinical work
- Helped fund discovery of CALR mutation, a genetic marker that explains the majority of JAK2 negative MPN

Leadership

MPN Research Foundation is governed by a Board of Directors and relies on its Scientific Advisory Panel for counsel on related matters and policies.

- **Chairman:** Robert Rosen,
rosen@mpnresearchfoundation.org
- **President:** Barbara Van Husen,
bvanhusen@mpnresearchfoundation.org

¹ Information obtained from MPN Research Foundation Financials.
<http://www.mpnresearchfoundation.org/Annual-Reports> . March 2014.